1 of 1
Story summary
- Health Secretary Robert F. Kennedy Jr. says the Food and Drug Administration (FDA) may allow about 14 peptides for domestic compounding pharmacies.
- Some healthcare professionals warn that looser regulations could pose health risks due to insufficient data.
- The peptide market is projected to grow, driven by consumer interest and social media promotion.
- Critics note many peptides lack FDA approval and may carry serious side effects, with uncertain FDA action.
